Quince Therapeutics, Inc.
QNCX
$1.61
$0.010.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.57% | -1.62% | -2.25% | 6.18% | -20.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.81% | 37.00% | 27.35% | 14.36% | -28.09% |
| Operating Income | -44.81% | -37.00% | -27.35% | -14.36% | 28.09% |
| Income Before Tax | -100.70% | -79.66% | -87.93% | -71.85% | 29.45% |
| Income Tax Expenses | 25.61% | 144.16% | 152.82% | 147.58% | 115.41% |
| Earnings from Continuing Operations | -100.49% | -81.07% | -90.06% | -73.63% | 28.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.49% | -81.07% | -90.06% | -73.63% | 28.37% |
| EBIT | -44.81% | -37.00% | -27.35% | -14.36% | 28.09% |
| EBITDA | -46.05% | -38.05% | -25.76% | -13.29% | 28.68% |
| EPS Basic | -83.89% | -56.03% | -59.53% | -48.18% | 38.20% |
| Normalized Basic EPS | -41.19% | -25.90% | -6.16% | 6.36% | 44.83% |
| EPS Diluted | -83.89% | -56.03% | -59.53% | -48.18% | 38.20% |
| Normalized Diluted EPS | -41.19% | -25.90% | -6.16% | 6.36% | 44.83% |
| Average Basic Shares Outstanding | 11.44% | 16.16% | 18.70% | 14.12% | 11.80% |
| Average Diluted Shares Outstanding | 11.44% | 16.16% | 18.70% | 14.12% | 11.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |